Many clinicians initiate treatment of COPD by prescribing long-acting beta agonist/inhaled
corticosteroid fixed-dose combinations (LABA/ICS FDCs), despite the growing evidence …

Background The differential risk of pneumonia among inhaled corticosteroid (ICS) use in
patients with COPD requires more investigation, especially regarding beclomethasone …

Chronic obstructive pulmonary disease (COPD) guidelines suggest using inhaled
corticosteroids (ICS) in patients with severe airflow limitation or those at high risk of …

Background Despite multiple available fixed-dose combinations (FDCs) of inhaled long-
acting β 2-agonists (LABAs) plus long-acting muscarinic antagonists (LAMAs) and LABAs …

Chronic obstructive pulmonary disease (COPD) is an under-recognized cause of morbidity
and mortality worldwide that imposes an ever increasing burden on the patient and society …

Introduction Combined inhaled long-acting beta-agonists and corticosteroids (LABA+ ICS)
are costly. They are recommended in severe or very severe chronic obstructive pulmonary …

Background Current guidelines recommend the use of inhaled corticosteroids (ICSs) added
to long-acting β 2-agonists (LABAs) for treatment of symptomatic patients with severe and …

Adding long-acting beta agonists (LABA) to inhaled corticosteroids (ICS) has been
associated with beneficial effects in COPD patients in randomized controlled trials and …

We read with great interest the meta-analysis recently published in the European
Respiratory Journal by Yang et al.[1] concerning the risk of major adverse cardiovascular …

Clinical trials in chronic obstructive pulmonary disease (COPD) patients have shown that the
long-term use of inhaled corticosteroids (ICS) in COPD patients reduced the number of …